Skip to main content
Equibles
VCYT logo

VCYT · Veracyte, Inc. · Webcasts, Transcripts & Audio

Track VCYT — free

Use VCYT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research VCYT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$50.28 +2.08 (+4.32%) Q2 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$4.12B
Shares
80.39M
Volume · Oct 27 1.81M Avg daily vol (3M) 1.38M

Veracyte, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Veracyte, Inc. (VCYT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-04
Veracyte, Inc. (VCYT) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-15
Veracyte, Inc. (VCYT) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-08-11
Veracyte, Inc. (VCYT) August 11, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-07-30
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
Confident tone Decipher prostate growth across risk categories ProSigna LDT launch in breast cancer Commercial expansion and sales force investment
Revenue
$150.32M
▲ 15.5% YoY
Diluted EPS
$0.31
Gross margin
72.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Veracyte, Inc. (VCYT) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-02
Veracyte, Inc. (VCYT) June 2, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
Veracyte, Inc. (VCYT) Q1 2026 Earnings Call Transcript
Confident tone Decipher Prostate Growth Afirma Thyroid Franchise Prosigna LDT Launch
Revenue
$139.07M
▲ 21.5% YoY
Diluted EPS
$0.35
▲ 288.9% YoY
Gross margin
72.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript
Confident tone Core testing business momentum (Decipher and Affirma) Clinical evidence and publications Profitability and cash generation
Revenue
$140.64M*
▲ 18.5% YoY
Gross margin
72.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript
Confident tone Decipher Prostate growth and momentum TrueMRD / MRD opportunity and platform expansion Capital allocation, M&A, and 2026 outlook
Revenue
$131.87M
▲ 13.8% YoY
Diluted EPS
$0.24
▲ 26.3% YoY
Gross margin
69.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript
Confident tone Decipher Prostate test growth Prosigna breast cancer test launch Afirma thyroid test performance
Revenue
$130.16M
▲ 13.8% YoY
Diluted EPS
$-0.01
▼ 114.3% YoY
Gross margin
69.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript
Confident tone Decipher Prostate growth and metastatic launch Afirma franchise and prior period collections headwind Minimal residual disease (MRD) platform
Revenue
$114.47M
▲ 18.2% YoY
Diluted EPS
$0.09
Gross margin
69.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-24
Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript
Confident tone Decipher Prostate Growth Financial Performance and Profitability MRD Platform Development
Revenue
$118.63M*
▲ 20.8% YoY
Gross margin
66.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript
Confident tone Decipher Prostate test growth and evidence Afirma thyroid test performance and reimbursement Financial results and profitability
Revenue
$115.86M
▲ 28.6% YoY
Diluted EPS
$0.19
Gross margin
68.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript
Confident tone Afirma Growth Profitability and Financial Performance Decipher Prostate Growth
Revenue
$114.43M
▲ 26.7% YoY
Diluted EPS
$0.07
Gross margin
68.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Veracyte, Inc. (VCYT) Q1 2024 Earnings Call Transcript
Confident tone Afirma thyroid testing Long-term growth strategy / IVD and platform expansion Decipher Prostate testing growth
Revenue
$96.84M
▲ 17.5% YoY
Diluted EPS
$-0.02
Gross margin
64.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Veracyte, Inc. (VCYT) Q4 2023 Earnings Call Transcript
Confident tone C2i Genomics / MRD acquisition Afirma franchise momentum Decipher Prostate growth and evidence
Revenue
$98.20M*
▲ 22.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Veracyte, Inc. (VCYT) Q3 2023 Earnings Call Transcript
Revenue
$90.11M
▲ 19.2% YoY
Diluted EPS
$-0.41
Gross margin
64.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Veracyte, Inc. (VCYT) Q2 2023 Earnings Call Transcript
Revenue
$90.32M
▲ 24% YoY
Diluted EPS
$-0.12
Gross margin
61.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Veracyte, Inc. (VCYT) Q1 2023 Earnings Call Transcript
Revenue
$82.42M
▲ 21.6% YoY
Diluted EPS
$-0.11
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
Veracyte, Inc. (VCYT) Q4 2022 Earnings Call Transcript
Revenue
$80.30M*
▲ 19.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Veracyte, Inc. (VCYT) Q3 2022 Earnings Call Transcript
Revenue
$75.59M
▲ 25.2% YoY
Diluted EPS
$-0.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Veracyte, Inc. (VCYT) Q2 2022 Earnings Call Transcript
Revenue
$72.86M
▲ 32.2% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Veracyte, Inc. (VCYT) Q1 2022 Earnings Call Transcript
Revenue
$67.78M
▲ 84.7% YoY
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Veracyte, Inc. (VCYT) Q4 2021 Earnings Call Transcript
Revenue
$67.34M*
▲ 95% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Veracyte, Inc. (VCYT) Q3 2021 Earnings Call Transcript
Revenue
$60.37M
▲ 94% YoY
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Veracyte, Inc. (VCYT) Q2 2021 Earnings Call Transcript
Revenue
$55.10M
▲ 166.2% YoY
Diluted EPS
$-0.13
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-15
Veracyte, Inc. (VCYT) Q1 2021 Earnings Call Transcript
Revenue
$36.70M
▲ 17.9% YoY
Diluted EPS
$-0.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-03
Veracyte, Inc. (VCYT) Q4 2020 Earnings Call Transcript
Revenue
$34.54M
▲ 16.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-02
Veracyte, Inc. (VCYT) Q3 2020 Earnings Call Transcript
Revenue
$31.12M
▲ 0.5% YoY
Diluted EPS
$-0.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Veracyte, Inc. (VCYT) Q2 2020 Earnings Call Transcript
Revenue
$20.70M
▼ 31.3% YoY
Diluted EPS
$-0.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-16
Veracyte, Inc. (VCYT) Q1 2020 Earnings Call Transcript
Revenue
$31.12M
▲ 5.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Veracyte, Inc. (VCYT) Q4 2019 Earnings Call
Revenue
$29.73M
▲ 15.5% YoY
Gross margin
67.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–32 of 32 webcasts
Key facts CIK 1384101 CUSIP 92337F107 13F (30d) 57 filings 57 filers Visit website Investor relations